Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Stopped Drug company decided to terminate all sponsored clinical studies involving rilotumumab.
Conditions
- MET Positive
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
- DRUG: Erlotinib Hydrochloride
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Rilotumumab
Sponsor
SWOG Cancer Research Network
Collaborators